NO20015111D0 - Kombinasjon av glykosylceramidsynteseinhibitorer og glykolipiddegraderende enzym ved terapi - Google Patents

Kombinasjon av glykosylceramidsynteseinhibitorer og glykolipiddegraderende enzym ved terapi

Info

Publication number
NO20015111D0
NO20015111D0 NO20015111A NO20015111A NO20015111D0 NO 20015111 D0 NO20015111 D0 NO 20015111D0 NO 20015111 A NO20015111 A NO 20015111A NO 20015111 A NO20015111 A NO 20015111A NO 20015111 D0 NO20015111 D0 NO 20015111D0
Authority
NO
Norway
Prior art keywords
disease
therapy
combination
degrading enzyme
synthesis inhibitors
Prior art date
Application number
NO20015111A
Other languages
English (en)
Other versions
NO20015111L (no
NO329035B1 (no
Inventor
Raymond Allen Dwek
Terence D Butters
Frances M Platt
David Priestman
Mylvaganam Jeyakumar
Original Assignee
Oxford Glycosciences Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences Uk Ltd filed Critical Oxford Glycosciences Uk Ltd
Publication of NO20015111D0 publication Critical patent/NO20015111D0/no
Publication of NO20015111L publication Critical patent/NO20015111L/no
Publication of NO329035B1 publication Critical patent/NO329035B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20015111A 1999-04-20 2001-10-19 Anvendelse av N-butyldeoksynojirimycin ved fremstilling av et medikament for behandling av en glykolipid-degraderingsforstyrrelse. NO329035B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9909066.4A GB9909066D0 (en) 1999-04-20 1999-04-20 Therapies
PCT/GB2000/001560 WO2000062779A1 (en) 1999-04-20 2000-04-20 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy

Publications (3)

Publication Number Publication Date
NO20015111D0 true NO20015111D0 (no) 2001-10-19
NO20015111L NO20015111L (no) 2001-12-12
NO329035B1 NO329035B1 (no) 2010-08-02

Family

ID=10851917

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015111A NO329035B1 (no) 1999-04-20 2001-10-19 Anvendelse av N-butyldeoksynojirimycin ved fremstilling av et medikament for behandling av en glykolipid-degraderingsforstyrrelse.

Country Status (15)

Country Link
US (2) US20020142985A1 (no)
EP (2) EP1321143A1 (no)
JP (1) JP4633939B2 (no)
AT (1) ATE243037T1 (no)
AU (1) AU775842B2 (no)
BR (1) BR0009913A (no)
CA (1) CA2368812C (no)
DE (1) DE60003409T2 (no)
ES (1) ES2200865T3 (no)
GB (1) GB9909066D0 (no)
IL (1) IL140379A (no)
MX (1) MXPA01010707A (no)
NO (1) NO329035B1 (no)
WO (1) WO2000062779A1 (no)
ZA (1) ZA200108417B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
CA2378776A1 (en) * 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
GB0006539D0 (en) * 2000-03-17 2000-05-10 Oxford Glycosciences Uk Ltd Therapies
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AU2002241853A1 (en) * 2001-01-12 2002-07-24 Oxford Glycosciences (Uk) Ltd. Mucopolysaccharidosis therapies
US20080185293A1 (en) * 2002-03-27 2008-08-07 Giselher Klose Method and Apparatus for Decontamination of Fluid with One or More High Purity Electrodes
MXPA05002292A (es) * 2002-08-27 2006-05-22 Nestle Sa Prevencion de tratamiento de tejido epitelial o perdida de pelo.
WO2006002283A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
US7429460B2 (en) 2003-01-15 2008-09-30 Yeda Research And Development Co., Ltd. Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2005123055A2 (en) * 2004-06-14 2005-12-29 Musc Foundation For Research Development Methods for treating inflammatory disorders
WO2006037069A1 (en) * 2004-09-28 2006-04-06 Allergan, Inc. Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions
RU2464973C2 (ru) * 2006-01-24 2012-10-27 НексБио, Инк. Технология изготовления макромолекулярных микросфер
SI1986612T1 (sl) 2006-02-07 2013-01-31 Shire Human Genetic Therapies, Inc. Stabilizirana spojina glukocerebrosidaze
BR122020010601B8 (pt) 2008-12-16 2021-07-27 Genzyme Corp conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
EP2411526A4 (en) * 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc MODULATORS OF GANGLIOSID BIOSYNTHESIS
NZ713967A (en) * 2009-07-28 2017-01-27 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
WO2012001641A1 (en) * 2010-06-30 2012-01-05 Actelion Pharmaceuticals Ltd Stable pharmaceutical compositions
KR20140138850A (ko) 2012-03-02 2014-12-04 샤이어 휴먼 지네틱 테라피즈 인크. Ｉｉｉ형 고셔병을 치료하기 위한 조성물 및 방법
US20150118221A1 (en) * 2012-05-08 2015-04-30 The John Hopkins University Compositions and methods for treating cardiac hypertrophy
JP2015527310A (ja) 2012-06-28 2015-09-17 アンサン バイオファーマ, インコーポレイテッドAnsun Biopharma, Inc. 下気道および中枢気道への送達用微粒子製剤ならびに製造方法
EP2874648A4 (en) 2012-07-17 2015-12-30 Amicus Therapeutics Inc CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
GB201407837D0 (en) * 2014-05-02 2014-06-18 Cambridge Entpr Ltd Methods of cancer therapy
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP7445251B2 (ja) * 2017-12-28 2024-03-07 国立大学法人 熊本大学 アルツハイマー病予防剤又は治療剤、アルツハイマー病予防用又は治療用組成物、及び方法
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
NL2021840B1 (en) 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
CA3164707A1 (en) 2020-02-03 2021-08-12 Ana Maria Garcia Collazo Combination therapy for treating mps1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US182767A (en) * 1876-10-03 Improvement in window-screens
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
DE2853573A1 (de) 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
DE3038901A1 (de) 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
US5151519A (en) 1990-05-07 1992-09-29 G. D. Searle & Co. Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
IL128036A (en) * 1996-07-15 2005-08-31 Univ Amsterdam Deoxynojirimycin derivatives comprising a polyclic alcohol group, pharmaceutical composition comprising a deoxynojirimycin derivative and uses thereof
US6610703B1 (en) * 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9909064D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
CA2378776A1 (en) * 1999-07-26 2001-02-01 G.D. Searle & Co. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Also Published As

Publication number Publication date
US20050075305A1 (en) 2005-04-07
ATE243037T1 (de) 2003-07-15
EP1321143A1 (en) 2003-06-25
CA2368812C (en) 2009-06-30
DE60003409T2 (de) 2004-05-19
CA2368812A1 (en) 2000-10-26
WO2000062779A1 (en) 2000-10-26
BR0009913A (pt) 2002-01-08
GB9909066D0 (en) 1999-06-16
ZA200108417B (en) 2003-03-26
JP4633939B2 (ja) 2011-02-16
DE60003409D1 (de) 2003-07-24
NO20015111L (no) 2001-12-12
AU4133200A (en) 2000-11-02
AU775842B2 (en) 2004-08-19
MXPA01010707A (es) 2002-08-20
IL140379A (en) 2006-09-05
EP1171128A1 (en) 2002-01-16
US20020142985A1 (en) 2002-10-03
IL140379A0 (en) 2002-02-10
US7348000B2 (en) 2008-03-25
JP2002542194A (ja) 2002-12-10
ES2200865T3 (es) 2004-03-16
EP1171128B1 (en) 2003-06-18
NO329035B1 (no) 2010-08-02

Similar Documents

Publication Publication Date Title
NO20015111L (no) Kombinasjon av glykosylceramidsynteseinhibitorer og glykolipiddegraderende enzym ved terapi
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
PT1007043E (pt) Metodo para o tratamento de doencas de armazeamento lisossomico com envolvimentode cns
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
AU2003226014A8 (en) Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
GB0223040D0 (en) Therapeutic compounds
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
ATE490786T1 (de) Behandlung von verletzungen des zentralen nervensystems
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
BR0009167A (pt) Inibidores de enzima impdh
WO2004028521A3 (en) Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
GB0225475D0 (en) Therapeutic agents
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
PT1049703E (pt) Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
NO307495B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av Parkinsons sykdom og Parkinsonske syndromer
DE60300021D1 (de) (S)-4-Amino-5-Chloro-2-Methoxy-N-[1-[1-(2-Tetrahydrofuryl-Carbonyl)-4-Piperidinylmethyl]-4-Piperidinyl]benzamid zur Behandlung von Magen-Darmbewegungskrankheiten
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
WO2005004814A3 (en) Sirt1 and genetic disorders
ATE403428T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
EA200501479A1 (ru) Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
WO2004055201A3 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees